The overall aims of this chapter are to compare the use of randomised evaluations in medicine and economics and to assess their ability to provide impartial evidence about causal claims. We will argue that there are no good reasons to regard randomisation as a sine qua non for good evidential practice in either science. However, in medicine, but not in development economics, randomisation can provide impartiality from the point of view of regulatory agencies. The intuition is that if the available evidence leaves room for uncertainty about the effects of an intervention (such as a new drug), a regulator should make sure that such uncertainty cannot be exploited by some party’s private interest. We will argue that randomisation plays an important role in this context. By contrast, in the field evaluations that have recently become popular in development economics, subjects have incentives to act strategically against the research protocol which undermines their use as neutral arbiter between conflicting parties.
CITATION STYLE
Teira, D., & Reiss, J. (2013). Causality, Impartiality and Evidence-Based Policy. In History, Philosophy and Theory of the Life Sciences (Vol. 3, pp. 207–224). Springer Science and Business Media B.V. https://doi.org/10.1007/978-94-007-2454-9_11
Mendeley helps you to discover research relevant for your work.